2025-10-23 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the information you provided. The report is in English, includes key figures, and adds insightful analysis.

**TransMedics Group Inc. (TMDX) Analysis**

TransMedics Group Inc. is a medical technology company focused on preserving and assessing organs for transplant.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return TMDX:** 200.89%
*   **Cumulative Return VOO:** 74.33%
*   **Spread:** 126.56%
*   **Spread Range:** Max 247.2, Min -74.5
*   **Current Relative Spread:** 61.2 (Indicates TMDX is performing in the upper range of its historical outperformance relative to VOO)

**Analysis of Alpha, Beta and other Data:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
| :--------- | :------ | :---- | :------ | :----- | :----- |
| 2019-2021  | -18.0% | 83.5% | -61.0% | -0.0 | 0.7    |
| 2020-2022  | 94.0%  | 83.5% | 95.0%  | 0.0  | 2.1    |
| 2021-2023  | 65.0%  | 80.5% | 64.0%  | 0.1  | 2.7    |
| 2022-2024  | 130.0% | 85.5% | 109.0% | 0.1  | 2.1    |
| 2023-2025  | 122.0% | 85.5% | 58.0%  | 0.3  | 4.1    |

*   **CAGR (Compound Annual Growth Rate):**  CAGR has been highly positive over the more recent 3-year periods (2020-2025).
*   **MDD (Maximum Drawdown):**  MDD is consistently high, indicating significant volatility.
*   **Alpha:**  Positive Alpha values suggest TMDX consistently outperforms the market (S&P 500) on a risk-adjusted basis.
*   **Beta:**  Low Beta values close to 0 indicate that the stock has very little correlation to the S&P 500.
*   **Cap(B):** Company Market Capitalization is steadily increasing

**2. Recent Price Action**

*   **Current Price:** 120.13
*   **Last Market:** {'price': 119.54, 'previousClose': 120.13, 'change': -0.49}
*   **5-day Moving Average:** 117.19
*   **20-day Moving Average:** 114.42
*   **60-day Moving Average:** 116.59

**Analysis:** The stock price closed slightly lower than the previous day. The price is above all three moving averages, which suggests a short to mid-term upward trend.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 58.18 (Neutral, neither overbought nor oversold)
*   **PPO:** 0.75 (Positive, indicating a potential upward trend)
*   **Hybrid Signal:** Buy 100% of cash (8 shares - Very Safe - MRI:0.90)
*   **Delta_Previous_Relative_Divergence:** 7.1 (+) (Short-term increase in relative outperformance)
*   **Expected Return (%):** 49.6% (Projected long-term outperformance vs. S&P 500 if investing now)

**Analysis:** The high MRI suggests a favorable investment environment. The RSI is neutral. The PPO and positive divergence support potential continued upward movement. The "Hybrid Signal" indicates a strong buy recommendation based on these indicators.

**4. Recent News & Significant Events**

*   **[2025-10-15]** Q3 2025 Earnings Report on October 29, 2025
*   **[2025-10-14]** Relative Strength Rating Upgrade (Investor's Business Daily)
*   **[2025-10-13]** Jefferies Initiates Buy Rating with $145 Price Target (MT Newswires)
*   **[2025-10-09]** Growth in Returns On Capital (Simply Wall St.)
*   **[2025-10-08]** Outstanding Healthcare Stock (Motley Fool)
*   **[2025-09-24]** Strong Growth Stock (Zacks)

**Analysis:** Recent news is overwhelmingly positive. Analyst upgrades, strong growth reports, and inclusion in "outstanding healthcare stock" lists suggest strong market sentiment. The upcoming earnings report is a key event to watch.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.75 on a 1-5 scale)
*   **Opinions:** 10 Analysts
*   **Target Price:**
    *   Average: $141.00
    *   High: $170.00
    *   Low: $114.00

**Analysis:** Analyst consensus is strongly bullish, with a significant upside potential based on the average price target.

**5. Recent Earnings Analysis**

| Date       | EPS  | Expected EPS |
| :--------- | :--- | :----------- |
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:** TMDX has consistently beaten EPS expectations in recent quarters, demonstrating strong financial performance. The notable outperformance in the most recent quarter is particularly encouraging.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| :--------- | :------ | :------------ |
| 2025-06-30 | $0.16B | 61.38%        |
| 2025-03-31 | $0.14B | 61.47%        |
| 2024-12-31 | $0.12B | 59.21%        |
| 2024-09-30 | $0.11B | 55.94%        |
| 2024-06-30 | $0.11B | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE    |
| :--------- | :------ | :----- |
| 2025-06-30 | $0.32B | 10.97% |
| 2025-03-31 | $0.27B | 9.64%  |
| 2024-12-31 | $0.23B | 3.00%  |
| 2024-09-30 | $0.21B | 2.01%  |
| 2024-06-30 | $0.19B | 6.42%  |

**Analysis:** Revenue is steadily increasing, and the profit margin is consistently high. Equity is also growing, and ROE is improving, indicating efficient use of capital.

**7. Overall Summary**

TransMedics Group Inc. (TMDX) shows very strong and positive signs.

*   **Strong Outperformance:** Significantly outperforms the S&P 500, and its current relative spread is in the upper range of its historical performance.
*   **Positive Momentum:** Recent price action, technical indicators, and news events suggest continued upward momentum.
*   **Analyst Support:** Strong buy consensus with a significant upside potential based on target prices.
*   **Earnings Beat:** Consistently beating EPS expectations.
*   **Solid Financials:** Increasing revenue, high profit margins, growing equity, and improving ROE.
*   **High Risk :** Although MDD is high, indicating significant volatility, MRI indicator shows High Investment Recommended.
*   **Recommendation:** Based on the analysis, TMDX appears to be a promising investment opportunity.
